

## **Peptomyc S.L. Expands its Patent Portfolio with a Patent Grant in Hong Kong for its Methods and Composition for the Treatment of Cancer**



Barcelona, 19<sup>th</sup> of August 2024

Peptomyc S.L., a company developing foundational mini-protein therapeutics for the treatment of cancer, announces today that the Company has been issued a patent by the Hong Kong Patent Office protecting its Methods and Composition of Matter.

"We are delighted to announce further protection of our mini-protein therapeutics in Hong Kong. This patent grant strengthens our patent portfolio that protects our unique mini-protein therapeutics, which are able to inhibit MYC, the most dysregulated oncogene in human cancer, in the major geographical areas in oncology," said Laura Soucek, CEO at Peptomyc S.L.

The Company currently maintains over 10 different patent families worldwide covering applications protecting Peptomyc S.L. first-in-modality mini-protein therapeutics in multiple oncological indications, and counts on the services of ABG Intellectual Property and Dechert LLP for the protection of its IP assets.

### **About Peptomyc**

Peptomyc ([www.peptomyc.com](http://www.peptomyc.com)) is a spin-off from VHIO – the Vall d’Hebron Institute of Oncology – and ICREA – the Catalan Institute of Research and Advanced Studies -, founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the MYC oncoprotein for cancer treatment and based on Dr. Soucek’s scientific research in Omomyc (the best direct MYC inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase 1 clinical trial with a direct MYC inhibitor.

### ***Disclosures Regarding Forward-Looking Statements***

*Peptomyc is including the following cautionary statement in this document to make applicable and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (or equivalent law) for any forward-looking statements made by, or on behalf of, the Company. Forward-looking statements include statements concerning plans, objectives, goals, projections, strategies, future events or performance, and underlying assumptions and other statements which are other than statements of historical facts. Certain statements contained herein, including, without limitation, those that are identified by the use of the words “anticipates,” “estimates,” “expects,” “forecasts,” “intends,” “plans,” “predicts,” “projects,” “believes,” “seeks,” “will,” “may” and similar expressions, are “forward-looking statements”. Forward-looking statements involve risks and uncertainties, which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company’s expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, but there can be no assurance that management’s expectations, beliefs, or projections will result or be achieved or accomplished.*